{"protocolSection": {"identificationModule": {"nctId": "NCT01370317", "orgStudyIdInfo": {"id": "1029-006"}, "secondaryIdInfos": [{"id": "MK-1029-006", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma", "officialTitle": "Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-06-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-12-27", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12-27", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-06-08", "studyFirstSubmitQcDate": "2011-06-08", "studyFirstPostDateStruct": {"date": "2011-06-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-22", "resultsFirstSubmitQcDate": "2018-08-22", "resultsFirstPostDateStruct": {"date": "2019-01-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-22", "lastUpdatePostDateStruct": {"date": "2019-01-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 27, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-1029", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-1029"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo for MK-1029"]}], "interventions": [{"type": "DRUG", "name": "MK-1029", "description": "Five (5) X 100 mg capsules, orally, once daily for 28 days", "armGroupLabels": ["MK-1029"]}, {"type": "DRUG", "name": "Placebo for MK-1029", "description": "Five (5) X 100 mg capsules, orally, once daily for 28 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Who Experienced One or More Adverse Events", "description": "An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.", "timeFrame": "Up to 42 days after initial dose of study treatment"}, {"measure": "Number of Participants Who Discontinued Study Treatment Due to An Adverse Event", "description": "An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.", "timeFrame": "Up to 28 days after initial dose of study treatment"}], "secondaryOutcomes": [{"measure": "Area Under the Concentration-Time Curve From Time 0 to 6 Hours (AUC0-6hr) of MK-1029", "description": "Blood was collected on Day 1 and Day 28 at predose and 1, 2, 3, 4 and 6 hours postdose for determining the Cmax of MK-1026.", "timeFrame": "Day 1 and Day 28: Predose, 1, 2, 3, 4, and 6 hours postdose"}, {"measure": "Maximum Plasma Concentration (Cmax) of MK-1029", "description": "Blood was collected on Day 1 and Day 28 at predose and 1, 2, 3, 4 and 6 hours postdose for determining the Cmax of MK-1026.", "timeFrame": "Day 1 and Day 28: Predose, 1, 2, 3, 4, and 6 hours postdose"}, {"measure": "Time to Maximum Plasma Concentration (Tmax) of MK-1029", "description": "Blood was collected on Day 1 and Day 28 at predose and 1, 2, 3, 4 and 6 hours postdose for determining the Tmax of MK-1026.", "timeFrame": "Day 1 and Day 28: Predose, 1, 2, 3, 4, and 6 hours postdose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* If female, must be of non-childbearing potential\n* Have a history of mild to moderate asthma for at least 6 months\n* Other than asthma, in general good health\n* Able to perform reproducible pulmonary function testing\n* Is a nonsmoker and/or has not used nicotine or nicotine-containing products for at least 12 months\n* Have body mass index (BMI) \u226517 kg/m\\^2, but \u226435 kg/m\\^2\n\nExclusion Criteria:\n\n* Demonstrate a decrease in absolute forced expiratory volume in 1 second (FEV1) of \\>20% from the Screening Visit to the Baseline Visit\n* Experience a decrease in AM or PM peak expiratory flow (PEF) below the Stability Limit on any 2 consecutive days prior to the Baseline Visit\n* Require the use of \\>8 inhalations per day of short-acting beta2-agonist metered dose inhaler (MDI) or \\>2 nebulized treatments per day of 2.5 mg albuterol, on any 2 consecutive days from the Screening Visit up to the Baseline Visit\n* Experience an exacerbation defined as a clinical deterioration of asthma, as judged by the clinical investigator, that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded medication (other than short-acting beta agonists \\[SABA\\]) at any time from the Screening Visit up to the Baseline Visit\n* Have been hospitalized for treatment of asthma or required oral corticosteroids for treatment of asthma within the past 6 months, or has ever required ventilator support for respiratory failure secondary to asthma\n* Require the chronic use of high-dose inhaled corticosteroids\n* Have been diagnosed with chronic obstructive pulmonary disease (COPD) or any other clinically relevant lung disease, other than asthma\n* Have a history of any illness that might confound the results of the study or poses additional risk to the participant\n* Have had recent (within 4 weeks of first dose) or ongoing upper or lower respiratory tract infection\n* Is nursing\n* Have a history of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Call for Information", "city": "Costa Mesa", "state": "California", "zip": "92626", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Call for Information", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Merck Sharp & Dohme", "city": "North Ryde", "country": "Australia", "geoPoint": {"lat": -33.79677, "lon": 151.12436}}, {"facility": "Merck Sharp & Dohme (New Zealand) Ltd.,", "city": "Wellington", "country": "New Zealand", "geoPoint": {"lat": -41.28664, "lon": 174.77557}}, {"facility": "MSD (Pty) LTD South Africa", "city": "Midrand", "country": "South Africa", "geoPoint": {"lat": -25.98953, "lon": 28.12843}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}, {"id": "FG001", "title": "Placebo", "description": "Participants received five 100 mg placebo-matching MK-1029 capsules, taken orally, once daily for 28 days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Participant withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}, {"id": "BG001", "title": "Placebo", "description": "Participants received five 100 mg placebo-matching MK-1029 capsules, taken orally, once daily for 28 days."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "27"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.4", "spread": "15.2"}, {"groupId": "BG001", "value": "41.6", "spread": "13.5"}, {"groupId": "BG002", "value": "40.8", "spread": "14.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Who Experienced One or More Adverse Events", "description": "An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.", "populationDescription": "All participants who received at least one dose of study drug", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 42 days after initial dose of study treatment", "groups": [{"id": "OG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}, {"id": "OG001", "title": "Placebo", "description": "Participants received five 100 mg placebo-matching MK-1029 capsules, taken orally, once daily for 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-Time Curve From Time 0 to 6 Hours (AUC0-6hr) of MK-1029", "description": "Blood was collected on Day 1 and Day 28 at predose and 1, 2, 3, 4 and 6 hours postdose for determining the Cmax of MK-1026.", "populationDescription": "All participants who received study drug and had evaluable concentration values for AUC0-6 hours on Day 1 and Day 28", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Day 1 and Day 28: Predose, 1, 2, 3, 4, and 6 hours postdose", "groups": [{"id": "OG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "745", "spread": "104"}]}]}, {"title": "Day 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "505", "spread": "275"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Plasma Concentration (Cmax) of MK-1029", "description": "Blood was collected on Day 1 and Day 28 at predose and 1, 2, 3, 4 and 6 hours postdose for determining the Cmax of MK-1026.", "populationDescription": "All participants who received study drug and had evaluable concentration values for Cmax on Day 1 and Day 28", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 1 and Day 28: Predose, 1, 2, 3, 4, and 6 hours postdose", "groups": [{"id": "OG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "295", "spread": "106"}]}]}, {"title": "Day 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "167", "spread": "273"}]}]}]}, {"type": "SECONDARY", "title": "Time to Maximum Plasma Concentration (Tmax) of MK-1029", "description": "Blood was collected on Day 1 and Day 28 at predose and 1, 2, 3, 4 and 6 hours postdose for determining the Tmax of MK-1026.", "populationDescription": "All participants who received study drug and had evaluable concentration values for Tmax on Day 1 and Day 28", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Day 1 and Day 28: Predose, 1, 2, 3, 4, and 6 hours postdose", "groups": [{"id": "OG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.00", "lowerLimit": "2.00", "upperLimit": "3.08"}]}]}, {"title": "Day 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.00", "lowerLimit": "1.98", "upperLimit": "4.00"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Treatment Due to An Adverse Event", "description": "An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.", "populationDescription": "All participants who received at least one dose of study drug", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 28 days after initial dose of study treatment", "groups": [{"id": "OG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days."}, {"id": "OG001", "title": "Placebo", "description": "Participants received five 100 mg placebo-matching MK-1029 capsules, taken orally, once daily for 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Up to 42 days after initial dose of study treatment", "description": "All participants who received at least one dose of study drug", "eventGroups": [{"id": "EG000", "title": "MK-1029", "description": "Participants received five 100 mg MK-1029 capsules, taken orally, once daily for 28 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 9, "otherNumAtRisk": 18}, {"id": "EG001", "title": "Placebo", "description": "Participants received five 100 mg placebo-matching MK-1029 capsules, taken orally, once daily for 28 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 3, "otherNumAtRisk": 9}], "otherEvents": [{"term": "Anorectal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Aphthous stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Otitis media viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Lethargy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Ecchymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Heat rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}